IFNA1 and neoplasm: Several studies provide compelling evidence that MSCs can be genetically engineered to deliver anti-tumor drugs (PTX, DOX) and immunomodulatory factors (IL-12, IL-24, IFN-Υ, IFN-β, TRAIL, PEDF, apotin, CDA/UPRT and CX3CL1) to target cells, thereby conferring anti-tumor/anti-metastatic actions [153].